

DART BUSINESS SERVICES, LLC

January 21, 2016

OTC Markets Group Inc.
304 Hudson Street, Second Floor
New York, NY 10013

**Re: Axiologix, Inc. ("AXLX.PK")
Annual Report for the 12 month period ended May 31, 2015**

Dear Sir or Madam:

The undersigned has acted as special counsel to Axiologix, Inc. (the "Issuer" or the "Company") for the purpose of reviewing the current information supplied by the Issuer in its Annual Report publicly disclosed by and published with the OTC Disclosure and News Service on January 21, 2016 for the period ending May 31, 2015. The opinion is solely for the information of the addressee hereof and OTC Market Group is entitled to rely on such letter in determining whether the Issuer has made adequate current Information publicly available within the meaning of Rule 144(c)(2) under the Securities Act of 1933.

The undersigned is a resident of the United States and authorized to practice law in the State of California. The jurisdiction covered by this letter is limited to the laws of the United States. The undersigned is permitted to practice before the U.S. Securities and Exchange Commission (the "SEC") and has not been prohibited from practice thereunder.

In connection with the rendering of this opinion, the undersigned has examined such corporate records and other documents and such questions of law as counsel considered necessary or appropriate for purposes of rendering this letter.

As to matters of fact, the undersigned relied on information obtained from public officials, officers of the Issuer and other sources, where such sources are believed to be reliable. In rendering this opinion, the undersigned has examined such corporate records and other documents, including, but not limited to, the following documents:

1. Certificate of Incorporation of the Company and all amendments thereto;
2. Bylaws of the Company;
3. Corporate minutes of the board of directors and shareholders; and
4. Such other corporate records and previous filings as were necessary and provided by management for purposes of this letter.

For the purposes of rendering this opinion, the undersigned has specifically also reviewed the following documents:

5. Supplemental Information Statement published through the OTC Disclosure and News Service on February 3, 2015;

6. Quarterly Report for the period ended November 30, 2014 published through the OTC Disclosure and News Service on January 21, 2015;
7. Supplemental Information Statement published through the OTC Disclosure and News Service on January 2, 2015;
8. Supplemental Information Statement published through the OTC Disclosure and News Service on October 23, 2014;
9. Quarterly Report for the period ended August 31, 2014 published through the OTC Disclosure and News Service on October 23, 2014;
10. Annual Report for the year ended May 31, 2014 published through the OTC Disclosure and News Service on October 17, 2014;
11. Supplemental Information Statement published through the OTC Disclosure and News Service on June 3, 2014;
12. Supplemental Information Statement published through the OTC Disclosure and News Service on April 24, 2014;
13. Supplemental Information Statement published through the OTC Disclosure and News Service on April 17, 2014;
14. Quarterly Report for the period ended February 28, 2013 published through the OTC Disclosure and News Service on April 7, 2014;
15. Supplemental Information Statement published through the OTC Disclosure and News Service on February 28, 2014;
16. Supplemental Information Statement published through the OTC Disclosure and News Service on December 2, 2013;
17. Quarterly Report for the period ended February 28, 2013 published through the OTC Disclosure and News Service on November 13, 2013;
18. Supplemental Information Statement published through the OTC Disclosure and News Service on September 19, 2013;
19. Supplemental Information Statement published through the OTC Disclosure and News Service on June 18, 2013;
20. Supplemental Information Statement published through the OTC Disclosure and News Service on May 7, 2013;
21. Quarterly Report for the period ended February 28, 2013 published through the OTC Disclosure and News Service on April 12, 2013;
22. Supplemental Information Statement published through the OTC Disclosure and News Service on February 26, 2013;
23. Quarterly Report for the period ended November 30, 2012 published through the OTC Disclosure and News Service on February 20, 2013;
24. Quarterly Report for the period ended August 31, 2012 published through the OTC Disclosure and News Service on November 15, 2012;
25. Supplemental Information Statement published through the OTC Disclosure and News Service on September 26, 2012;
26. Supplemental Information Statement published through the OTC Disclosure and News Service on September 14, 2012;

27. Supplemental Information Statement published through the OTC Disclosure and News Service on August 13, 2012;
28. Annual Report for the year ended May 31, 2012 published through the OTC Disclosure and News Service on August 2, 2012;
29. Supplemental Information Statement published through the OTC Disclosure and News Service on June 7, 2012;
30. Supplemental Information Statement published through the OTC Disclosure and News Service on May 17, 2012;
31. Quarterly Report for the period ended February 29, 2012 published through the OTC Disclosure and News Service on April 20, 2012; and
32. Company Initial Information and Disclosure Statement for the years ended May 31, 2010 and 2011 and interim period ended November 30, 2011 filed on April 20, 2012.

The undersigned has assumed that (i) all information contained in all documents reviewed by me is true and correct, (ii) all signatures on these documents reviewed by me are genuine, (iii) all documents submitted to me as originals are true and complete, (iv) all documents submitted to me as copies are true and complete copies of the originals thereof, and (v) each natural person signing any document reviewed had the legal capacity to do so. For the purposes of rendering this opinion, I have assumed that no person or entity has engaged in fraud or misrepresentation regarding the inducement relating to, or the execution or delivery of, the documents reviewed. Furthermore, I express no opinion as to the validity of any of the assumptions, form or content of any financial or statistical data contained therein. The terms used in this opinion shall have the meaning ascribed to them in the documents relied upon in rendering this opinion

On January 21, 2016, the Issuer posted on the OTC Markets its financial statements for the twelve months ended May 31, 2015, including, by reference, its current unaudited consolidated balance sheets, consolidated statement of cash flow and consolidated statement of stockholders' equity. The undersigned has reviewed such document and finds it to be suitable for public disclosure.

Based on the examination set forth above, the undersigned is of the opinion that the information (i) constitutes "adequate current public information" concerning the Securities and the Issuer and "is available" within the meaning of Rule 144(c)(2) under the Securities Act, (ii) includes all of the information that a broker-dealer would be required to obtain from the Issuer to publish a quotation for the Securities under Rule 15c2-11 under the Securities Exchange Act of 1934, as amended, (iii) complies as to form with the OTC Markets' Guidelines for Providing Adequate Current Information, which are located on the Internet at www.otcm Markets.com, and (iv) has been posted through the OTC Disclosure and News Service.

The Issuer's unaudited interim financial statements for the 12 months ended May 31, 2015 were prepared by Vincent Browne, the Company's Chief Executive Officer, Chief Financial Officer & Chairman. Mr. Browne graduated from the University College in Dublin, Ireland with a Bachelor of Commerce (Accounting) Degree in 1991. Since then Mr. Browne has worked in various accounting and management functions within multinational, private and U.S. public

companies. The Company has represented to me that the financial statements were prepared in accordance with U.S. Generally Accepted Accounting Principles.

The Issuer's transfer agent is American Stock Transfer & Trust Company, LLC, 6201 15th Avenue Brooklyn, NY 11219, and is registered with the SEC. The method used to confirm the number of outstanding shares of the Issuer's stock as set forth in the Disclosure Statement was through email contact with the transfer agent and receipt of written confirmation as to the number of outstanding shares.

The undersigned has (i) previously personally met with management and the directors of the Issuer, (ii) reviewed the information, as amended, published by the Issuer on the OTC Markets Disclosure and News Service, and (iii) discussed the information with management.

To the best of my knowledge, after inquiry of management and the directors of the Issuer, neither the Issuer of the Securities, nor any 5% holder, nor counsel is currently under investigation by any federal or state regulatory authority for any violation of federal or state securities laws.

OTC Markets is entitled and authorized to rely on this letter in determining whether the Company has made adequate information publicly available within the meaning of Rule 144(c)(2) under the Securities Act. No person or entity other than OTC Markets is entitled to rely on this letter, but permission is granted to OTC Markets to publish this letter in the OTC Markets News Service for viewing by the public and regulators. This letter may not be used or relied upon by any other person for any other purpose whatsoever, without in each instance, the undersigned's prior written consent. This opinion is based on the undersigned's knowledge of the law and facts as of the date hereof. The undersigned assumes no duty to communicate with you with respect to any other matter which comes to the undersigned's attention hereafter.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'T. Durant', followed by a horizontal line extending to the right.

Taliesin Durant, Esq.
Founder & President
DART Business Services, LLC